PARP inhibitors (PARPi) are approved for treating recurrent, advanced BRCA1/2-mutant high-grade serous ovarian cancer and have shown improved overall survival mainly in patients with germline and somatic BRCA1/2 pathogenic mutations or homologous recombination deficiency (HRD) [9], highlighting the importance of these genetic mutations as both prognostic and predictive indicators in a subset of ovarian cancer patients. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.